These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30034614)

  • 21. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.
    Christiansen E; Hansen SV; Urban C; Hudson BD; Wargent ET; Grundmann M; Jenkins L; Zaibi M; Stocker CJ; Ullrich S; Kostenis E; Kassack MU; Milligan G; Cawthorne MA; Ulven T
    ACS Med Chem Lett; 2013 May; 4(5):441-445. PubMed ID: 23687558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
    Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
    Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
    PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-Fluorination.
    Huang H; Meegalla SK; Lanter JC; Winters MP; Zhao S; Littrell J; Qi J; Rady B; Lee PS; Liu J; Martin T; Lam WW; Xu F; Lim HK; Wilde T; Silva J; Otieno M; Pocai A; Player MR
    ACS Med Chem Lett; 2019 Jan; 10(1):16-21. PubMed ID: 30655940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A New Pain Regulatory System via the Brain Long Chain Fatty Acid Receptor GPR40/FFA1 Signal].
    Nakamoto K
    Yakugaku Zasshi; 2017; 137(2):199-204. PubMed ID: 28154332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentiation of Glucose-stimulated Insulin Secretion by the GPR40-PLC-TRPC Pathway in Pancreatic β-Cells.
    Yamada H; Yoshida M; Ito K; Dezaki K; Yada T; Ishikawa SE; Kakei M
    Sci Rep; 2016 May; 6():25912. PubMed ID: 27180622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo.
    Hauge M; Vestmar MA; Husted AS; Ekberg JP; Wright MJ; Di Salvo J; Weinglass AB; Engelstoft MS; Madsen AN; Lückmann M; Miller MW; Trujillo ME; Frimurer TM; Holst B; Howard AD; Schwartz TW
    Mol Metab; 2015 Jan; 4(1):3-14. PubMed ID: 25685685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1.
    Xiong Y; Swaminath G; Cao Q; Yang L; Guo Q; Salomonis H; Lu J; Houze JB; Dransfield PJ; Wang Y; Liu JJ; Wong S; Schwandner R; Steger F; Baribault H; Liu L; Coberly S; Miao L; Zhang J; Lin DC; Schwarz M
    Mol Cell Endocrinol; 2013 Apr; 369(1-2):119-29. PubMed ID: 23403053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
    Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity.
    Ou HY; Wu HT; Hung HC; Yang YC; Wu JS; Chang CJ
    Am J Physiol Endocrinol Metab; 2013 Mar; 304(6):E668-76. PubMed ID: 23341496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GPR40 reduces food intake and body weight through GLP-1.
    Gorski JN; Pachanski MJ; Mane J; Plummer CW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Cheewatrakoolpong B; Howard AD; Colletti SL; Trujillo ME
    Am J Physiol Endocrinol Metab; 2017 Jul; 313(1):E37-E47. PubMed ID: 28292762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.
    Negoro N; Sasaki S; Ito M; Kitamura S; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
    J Med Chem; 2012 Feb; 55(4):1538-52. PubMed ID: 22242551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.
    Song F; Lu S; Gunnet J; Xu JZ; Wines P; Proost J; Liang Y; Baumann C; Lenhard J; Murray WV; Demarest KT; Kuo GH
    J Med Chem; 2007 Jun; 50(12):2807-17. PubMed ID: 17500511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.
    Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T
    Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a novel potent GPR40 full agonist.
    Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion.
    Itoh Y; Hinuma S
    Hepatol Res; 2005 Oct; 33(2):171-3. PubMed ID: 16214394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
    Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME
    PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.